Home » Stocks » AKUS

Akouos, Inc. (AKUS)

Stock Price: $11.46 USD -0.03 (-0.26%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 395.82M
Revenue (ttm) n/a
Net Income (ttm) -54.25M
Shares Out 34.45M
EPS (ttm) -2.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $11.46
Previous Close $11.49
Change ($) -0.03
Change (%) -0.26%
Day's Open 11.67
Day's Range 11.33 - 11.73
Day's Volume 46,880
52-Week Range 10.84 - 30.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- Leadership team expanded with appointment of Kathy Reape, M.D. as chief development officer

2 months ago - GlobeNewsWire

- Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression sufficie...

2 months ago - GlobeNewsWire

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabli...

2 months ago - GlobeNewsWire

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing ...

2 months ago - GlobeNewsWire

BOSTON, April 27, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearin...

3 months ago - GlobeNewsWire

Akouos, Inc. (AKUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago - Zacks Investment Research

BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearin...

3 months ago - GlobeNewsWire

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disab...

3 months ago - GlobeNewsWire

- In 2020, continued to advance genetic medicine pipeline with execution of IND-enabling studies for AK-OTOF and general alignment with FDA on the path to a 2022 IND submission for AK-antiVEGF

4 months ago - GlobeNewsWire

Akouos (AKUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they believe they can profit remarkably from their investments after the market has reassesse...

Other stocks mentioned: PMVP, TARA
6 months ago - GuruFocus

About AKUS

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibul... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2020
Stock Exchange
NASDAQ
Ticker Symbol
AKUS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Akouos stock is "Strong Buy." The 12-month stock price forecast is 30.00, which is an increase of 161.78% from the latest price.

Price Target
$30.00
(161.78% upside)
Analyst Consensus: Strong Buy